Lod, Israel - P-Cure, an emerging leader in developing new innovative proton therapy solutions, today announced that it has signed a development agreement with Philips Healthcare that defines the framework and associated conditions for collaboration in developing proton therapy solutions.

P-Cure collaborates with Philips Healthcare in developing innovative, cost effective oncology radiation solutions, using the Philips CT imaging technology, defining an advanced standard of care for the benefit of cancer patients worldwide.

"We are proud to be working with Philips Healthcare, a global leader in cancer management, and look forward to provide the next generation proton therapy systems, reducing cost and improving treatment quality and accessibility" said Michael Marash, PhD, Chief Executive Officer of P-Cure.
About P-Cure

P-Cure Ltd. is developing and marketing innovative patient-focused solutions for the Proton Therapy market that significantly reduce costs associated with creating and operating proton treatment centers. The P-Cure solution offers increased flexibility for fixed-beam settings, with the ability to treat a significantly larger number of indications, reducing the need for large and expensive gantry systems, with a corresponding increase in patient throughput. As a result, customers benefit from significant reductions in construction, equipment, and facility costs while increasing the effectiveness. P-Cure obtained FDA 510(k) clearance for P-ART™, its core software system for patient positioning in October 2010. Founded in 2007, P-Cure is a privately held company with offices in Israel and the U.S.

Contact Persons

Stephen Jacobs, Marketing Director
Stephen.jacobs@p-cure.com

Michael Marash, CEO
Michael.marash@p-cure.com
+972-8-6373030

More HCB News